NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”, of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Petco To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Petco between January 14, 2021 and June 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 30, 2025 (GLOBE NEWSWIR ...

NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) between January 14, 2021 and June 5, 2025, both dates inclusive (the “Class Period”), of the important August 29, 2025 lead plaintiff deadline. SO WHAT: If you purchased Petco securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

诉讼调查 - 律师事务所Faruqi & Faruqi正在调查RxSight公司潜在的证券法违规行为 并提醒投资者在2025年9月22日前申请成为集体诉讼的首席原告 [2] - 调查涉及RxSight在2024年11月7日至2025年7月8日期间可能存在的虚假陈述或信息披露不充分问题 [1][4] - 律师事务所自1995年成立以来已为投资者追回数亿美元损失 在纽约 宾夕法尼亚 加利福尼亚和乔治亚州设有办公室 [3] 公司财务问题 - RxSight在2025年第二季度财报中披露LDD销售额 LAL使用率和整体收入显著下降 并将2025年全年指引中值下调约4250万美元 [5] - 公司CEO承认"过去几个季度的采用挑战"是LDD销售停滞的主要原因 [5] - 财报公布后次日 公司股价单日暴跌4.84美元(37.8%)至7.95美元 成交量异常放大 [5] 指控内容 - 指控称RxSight未如实披露公司面临"采用挑战"和结构性问题 导致销售和使用率下降 [4] - 公司被指控夸大产品需求 且不太可能实现其先前发布的2025财年财务指引 [4] - 指控认为公司高管关于业务运营和前景的积极陈述存在重大误导性且缺乏合理依据 [4] 法律程序 - 法院将指定在索赔中具有最大财务利益的投资者作为首席原告 该原告需能代表集体诉讼成员的利益 [6] - 集体诉讼成员可选择自行聘请律师申请担任首席原告 或选择不作为而保留缺席成员身份 [6] - 律师事务所呼吁了解RxSight行为的知情人士(包括举报人 前员工 股东等)提供信息 [7]

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025. SO WHAT: If you purchased RxSight securities during the Class P ...

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Flywire Corporation (“Flywire” or the “Company”) (NASDAQ: FLYW) between February 28, 2024 and February 25, 2025, inclusive. For more information, submit a form at Flywire Corporation Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, o ...

公司事件 - 律师事务所Faruqi & Faruqi正在调查Replimune Group Inc潜在证券索赔案件 并提醒投资者在2025年9月22日前申请成为集体诉讼的首席原告[3] - 诉讼指控公司及高管违反联邦证券法 包括对IGNYTE试验前景的虚假陈述 以及未披露已知的重大问题 导致FDA认定该试验不充分且不受控[5] - 2025年7月22日盘前 Replimune公告收到FDA关于RP1生物制剂许可申请的完全回复函(CRL) 指出IGNYTE试验未能提供有效性的实质证据[6] 市场反应 - 2025年7月22日盘中 Replimune普通股股价暴跌73%[7] - 受影响投资者定义为在2024年11月22日至2025年7月21日期间损失超过5万美元的股东[1] 法律程序 - 法院将指定财务利益最大的适格投资者作为首席原告 代表集体诉讼成员主导诉讼进程[8] - 律师事务所鼓励知情者提供线索 包括举报人、前员工和股东等[9]

NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Centene Corporation (NYSE: CNC) between December 12, 2024 and June 30, 2025, both dates inclusive (the “Class Period”), of the important September 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Centene common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

诉讼背景 - 律师事务所Bleichmar Fonti & Auld LLP对RxSight公司及其高管提起集体诉讼 指控其违反联邦证券法 [1] - 诉讼依据为《1934年证券交易法》第10(b)和20(a)条款 案件由美国加州中区法院受理 案号25-cv-01596 [2] 公司业务 - RxSight主营白内障手术用光可调节人工晶体(LAL)及配套设备(LDD)的产销 其LAL产品可通过非侵入性光疗实现术后定制化调整 [3] 指控核心 - 公司在关键时期夸大LAL和LDD销售数据 未披露产品存在的"市场接受度挑战"问题 实际自2024年起已出现使用量增速放缓 [4] 股价影响 - 2025年4月3日因下调全年营收指引 股价单日暴跌38% 从26.12美元/股跌至16.21美元/股 [5] - 2025年7月8日再次下调营收预期 股价再跌38% 从12.79美元/股跌至7.95美元/股 主因是2024年以来LAL使用量增长乏力 [6] 律所背景 - 代理律所BFA在证券集体诉讼领域具有国际声誉 曾为特斯拉案追回9亿美元 为梯瓦制药案追回4.2亿美元 [8][9]

NEW YORK, July 23, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, inclusive. For more information, submit a form at RxSight, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us at (212) ...